Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Operating Leases for 3 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 8.6% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, down 8.6% year-over-year, with the annual reading at $7.6 million for FY2025, 8.6% down from the prior year.
  • Operating Leases for Q4 2025 was $7.6 million at Centessa Pharmaceuticals, down from $8.4 million in the prior quarter.
  • The five-year high for Operating Leases was $9.7 million in Q1 2023, with the low at $7.6 million in Q4 2025.
  • Average Operating Leases over 3 years is $8.8 million, with a median of $8.8 million recorded in 2023.
  • Peak annual rise in Operating Leases hit 0.0% in 2025, while the deepest fall reached 8.6% in 2025.
  • Over 3 years, Operating Leases stood at $8.9 million in 2023, then fell by 6.77% to $8.3 million in 2024, then dropped by 8.6% to $7.6 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $7.6 million, $8.4 million, and $8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.